Lilly Cannot Sue Anyone for Selling an Unapproved Drug. So What Is the Claim?

A reader asked the sharpest question I have had about the Lilly suits, and I did not have a good answer on hand. It goes like this.

Retatrutide is not approved. Lilly does not sell it to anybody. The sellers are not putting a Lilly logo on the vial, and they are not pretending to be Lilly. So what is the actual injury? You cannot lose a sale you were never allowed to make.

That is not a naive question. I think it is most of the case.

What Lilly cannot sue for

Start with the thing that surprised me. Lilly cannot sue anyone for selling an unapproved drug.

The Food, Drug, and Cosmetic Act is the law that makes selling unapproved drugs illegal, and it has no private right of action. That is a plain way of saying only the government gets to enforce it. The FDA can act. The Department of Justice can act. A competitor, even the competitor whose molecule it is, cannot walk into court and say "these people are selling an unapproved drug, make them stop." That door is closed to Lilly.

Which is why Lilly's own announcement is worth reading twice. It talks at length about illegality, unregulated foreign manufacturers, and public health. It calls the situation an urgent public health crisis. What it does not do, anywhere, is name a legal claim.

That is not evasiveness. It is the shape of the problem. The strongest thing Lilly can say in a press release is the thing it cannot say in a complaint.

So what is left

The route that stays open is false advertising, under section 43(a) of the Lanham Act. That statute does have a private right of action, and it is not about approval status at all. It is about whether you said something false in commerce.

This reframes the whole case, and I think it explains a detail from the first piece on these suits that I passed over too quickly. Lilly is not primarily suing over the existence of the product. It is suing over the sentences printed around it. Research use only, when Lilly alleges the intent was human use. Claims about grade and purity. Descriptions of what the material is and where it came from. Those are statements, and statements can be false in a way a regulatory status cannot.

I want to be careful here, because this is the part of the story I could not fully verify. I tried to read the actual complaints and could not get to them. Lilly has not itemised its counts publicly, and the trade coverage does not list them either. So what follows is the mechanism these suits have to run through, not a transcript of what is pleaded. If the filings show something different, this piece gets corrected like anything else.

The hinge, and it is a good one

Here is where your instinct about lost sales gets its answer, and the answer is genuinely interesting.

In 2014 the Supreme Court decided a case called Lexmark v. Static Control. It was unanimous, written by Scalia, and it settled who is allowed to bring a false advertising claim. The test it produced is that you must plead an injury to a commercial interest in reputation or sales.

Read that again, because the word doing the work is "or". Reputation counts on its own. You do not need a lost sale. The Court also said the parties do not need to be competitors at all.

Now apply it. Lilly's asset is not a stock of retatrutide it failed to sell this quarter. Its asset is a molecule it has spent years and an enormous amount of money carrying through Phase 3, which it intends to launch, and whose reputation is being built right now by people it has no control over. If somebody is injured by material sold under that name, sourced from a manufacturer nobody has inspected, the harm does not land on the seller's brand. It lands on the name of the drug.

That is a commercial interest in reputation, injured before a single approved unit has ever been sold. Lexmark says that is enough to get through the door.

The naming problem, which cuts the other way from how it looks

Your point about the label is right, and it is right in a more specific way than you may have meant.

Retatrutide is not a Lilly brand name. It is the nonproprietary name, the generic one, the kind of name that exists so every scientist on earth can refer to the same molecule. Lilly has not announced a commercial brand name yet. There is no Zepbound equivalent for this one, because there is no product.

So the sellers genuinely are not infringing a trademark in the ordinary sense. There is no logo to copy and no brand name to pass off. If you were expecting this to be a counterfeiting case, it is not one.

But notice what that does to the reputational argument. It strengthens it. When a brand name gets dragged through the mud, the company can eventually distance the brand. When the generic name is the thing being used, there is nowhere to move. Lilly will launch under a brand, and underneath that brand, on every label and in every prescribing conversation, will be the word retatrutide. Whatever that word comes to mean over the next two years, it means it permanently.

That is the injury, and it is being caused right now, which is presumably why the suits came now rather than after approval.

What I would watch

Three things, and none of them require a law degree.

Whether the complaints attack literally false statements or statements that need the FDA to interpret them. Courts have been picky about this line, because a false advertising claim that is really an unapproved-drug claim in a costume tends to get thrown out. Attacking "research use only" as a factually false description of an actual transaction is the version most likely to survive. Attacking the sale itself is the version that runs into the closed door from earlier.

Whether any defendant fights or they all fold. Six defendants is a lot of chances for one of them to litigate and produce a written ruling, which is worth more to everybody's understanding than a stack of quiet settlements.

And whether the reputational theory gets tested at all. It is plausible on Lexmark. Whether a court accepts it for a drug that does not yet legally exist as a product is a genuinely open question, and I have not found a case squarely on it.

I am not a lawyer, and none of this is legal advice. But the reader who asked the question had already done the useful part, which was refusing to accept "they are suing them" as an explanation of anything. The claim is not the compound, and the lawsuit is not the legal theory.